Dengvaxia Controversy: Impact on Vaccine Hesitancy
Khunsha Fatima, Najah Irfan Syed … The quest for a suitable vaccine for dengue has been ongoing for the last six decades. In one such effort, Sanofi, one of the biggest multinational pharmaceutical companies, developed the world’s first dengue vaccine – Dengvaxia. The vaccine is now approved in 19 countries and was used in vaccination […]
Stanford Study Finds Vaccine mRNA and Spike Protein Persist in the Body for Months Following Vaccination – But Not Following Infection
Will Jones A study from Stanford University, published in Cell, has found that vaccine mRNA and spike protein persist in lymph nodes for up to two months following the second vaccine dose. This is in contrast to what happens following infection, where spike protein was found only rarely … The high concentration in the blood of spike […]
I Don’t Think It’s Myocarditis, I Think It’s Injection-Induced Cardiac Amyloidosis
Jessica Rose Cardiac Amyloidosis or Stiff Heart Syndrome is caused by deposits of abnormal proteins in the heart tissue. This results in the heart ceasing to function properly due to the replacement of normal heart muscle tissue with amyloids. Cardiac Amyloidosis is associated with thick heart walls and large atria. It can affect electrical conductivity […]
Serious Adverse Events of Special Interest Following mRNA Vaccination in Randomized Trials
Joseph Fraiman et al. Pfizer and Moderna mRNA COVID-19 vaccines were associated with an increased risk of serious adverse events of special interest, with an absolute risk increase of 10.1 and 15.1 per 10,000 vaccinated over placebo baselines of 17.6 and 42.2 (95% CI -0.4 to 20.6 and -3.6 to 33.8), respectively. Combined, the mRNA […]
Increased Emergency Cardiovascular Events Among Under-40 Population in Israel During Vaccine Rollout and Third COVID-19 Wave
Christopher L.F. Sun, Eli Jaffe, Retsef Levi Cardiovascular adverse conditions are caused by coronavirus disease 2019 (COVID-19) infections and reported as side-effects of the COVID-19 vaccines. Enriching current vaccine safety surveillance systems with additional data sources may improve the understanding of COVID-19 vaccine safety. Using a unique dataset from Israel National Emergency Medical Services (EMS) […]
Adverse Events of Special Interest (AESIs) for Covid-19 Vaccines Surveillance
Public Health Ontario Adverse Events of Special Interest (AESIs) for COVID-19 Vaccines Surveillance Following the authorization of novel Coronavirus Disease 2019 (COVID-19) vaccines in Canada, post- marketing surveillance is being conducted to monitor the safety of these new vaccines throughout the implementation of the immunization program. Provincial reporting of adverse events following immunization (AEFIs) to […]
Pfizer documents: Cumulative Analysis of Post-authorization Adverse Event Reports
Released April 1, 2022 Although the report contains a list of adverse events spanning 9 pages (Appendix 1), Pfizer still concludes that these findings of their “signal detection analyses are consistent with the known safety profile” of their product BNT162b2 and the “cumulative post-marketing experience confirms a favourable benefit-risk balance”.
